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Fig 2. Biopsy showing, in the dermis, focal necrosis of the
sebaceous gland and presence of ghost cells with loss of
hematoxylin stain in the pilosebaceous unit. Note that
dermal collagen does not show fibrosis or sclerosis.
(Hematoxylin-eosin stain; original magnification: 340.)
Fig 1. Supraumbilical cutaneous lesions 3 days after
transcatheter arterial chemoembolization. Violaceous
indurated plaques over the navel.
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L-shaped angle of the HFA.1
The skin lesions consist of violaceous, indurated,
and painful plaques in the supraumbilical area that
can evolve to complete necrosis of the abdominal
wall.3 Histology is nonspecific, displaying sclerosis
with vascular thrombosis and focal fat necrosis.3
Treatment consists of local application of cold
packs, topical antibiotics, and surgical debridement
if necessary. In 1 case, oral pentoxifylline was used
with good results.3
This complication might be avoided by prophy-
lactic embolization of the proximal portion of the
HFA usingmicrocoils, thus preventing the flow of the
chemotherapeutic agent to this artery.3,4 Because the
abdominal wall is also irrigated by branches of the
superior and inferior epigastric arteries, which
communicate with the HFA, embolization wouldOpen access under CC BY-NC-ND license.not cause ischemic lesions on the skin.4 Because
the HFA is a small caliber artery that is sometimes
difficult to access, Wang et al5 proposed the prophy-
lactic use of ice packs on those patients whose HFA
cannot be embolized.
We think it is important to acknowledge the risk of
developing supraumbilical cutaneous lesions after
TACE. Although it is a rare complication of this
procedure, its frequency will probably grow in the
future due to the increased use of TACE in the
treatment of unresectable liver tumors.
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Merkel cell carcinoma presenting as right leg
edema in a multiple myeloma patient
To the Editor: A 61-year-old man with intractable
vomiting, fatigue, and acute renal failure was accu-
rately diagnosed with stage III multiple myeloma as
Fig 1. Merkel cell carcinoma. Computed tomographye
guided needle biopsy of the nodal mass.
Fig 2. Merkel cell carcinoma. Cutaneous in-transit
metastases.
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Letters e51the initial neoplasm. He was treated with lenalido-
mide, dexamethasone, and bortezomib with an
excellent response. Four months after treatment
completion, he presented with persistent right lower
extremity edema and pain. Deep vein thrombosis
and renal artery stenosis were excluded with
Doppler ultrasound. Physical examination revealed
pitting edema to the knee with dusky erythema and
scaling; laboratory investigations were significant for
kidney failure. A computed tomography (CT) scan of
the abdomen and pelvis revealed a 14- 3 7-cm
retroperitoneal nodal mass obstructing the ureters
and bilateral hydronephrosis. A CT-guided biopsy
revealed Merkel cell carcinoma (MCC) (Fig 1). No
cutaneous lesions were evident at that time. The
patient received external beam radiation therapy for
the mass, which alleviated the edema and pain.
Shortly thereafter he returned with painful, firm,
erythematous nodules on his distal right leg, which
demonstrated metastatic MCC on needle biopsy. He
began a palliative regimen of carboplatin and
etoposide, which resulted in pancytopenia and
sepsis. The lesions recurred throughout his leg,
thigh, and foot 1 month later with ulceration and
bleeding (Fig 2). He subsequently began gemcita-
bine, which resulted in anemia requiring trans-
fusions and metastatic progression. Chemotherapy
was changed to temozolomide. Six months later,
widely disseminated cutaneous lesions involved
the left lower extremity, abdomen, and chest.
Chemotherapy was discontinued in favor ofpalliative measures, and the patient died of disease
progression 3 months later.
MCC is a rare, highly aggressive neuroendocrine
malignancy with a high rate of local recurrence and
metastasis, and the diagnosis carries a poor prog-
nosis. Increasing evidence has demonstrated a rela-
tionship between MCC and impaired immunity,
whether iatrogenic after organ transplantation, ac-
quired due to human immunodeficiency virus, or
intrinsic due to malignancy.1 This association led to
the discovery of the Merkel cell polyomavirus and its
detection in themajority ofMCC tumors, revealing an
increased frequency of virus reactivation in immu-
nocompromised patients.2 Recent case reports have
suggested that primary cancers, especially chronic
lymphocytic leukemia, non-Hodgkin lymphoma,
and multiple myeloma, may predispose patients to
development of MCC. Howard et al3 demonstrated a
greater than 3-fold increased risk of primary MCC
development after multiple myeloma diagnosis with
a median latency of 3.4 years.
This case of MCC presenting with acute renal
failure and impaired lower extremity venous
drainage causing edema illustrates that the diagnosis
of MCC may have been confounded by the patient’s
preexisting malignancy and residual kidney impair-
ment due to light chain deposition. We also believe
that persistent lymphedema of the right leg, which
was likely the primary site of disease, masked the
detection of this second primary malignancy. When
treating immunocompromised patients, especially
those with lymphohematopoietic malignancies, vig-
ilance for the development of MCC should be
considered, in that early detection can greatly impact
prognosis and survival. This case reemphasizes that
cutaneous malignancy risk assessment should be
performed in the initial stages of management for
every immunocompromised patient.
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ceous papules on the extensor forearm.Photosensitive lichenoid drug eruption to
capecitabine
To the Editor: A 75-year-old Caucasian woman
undergoing capecitabine treatment for metastatic
breast cancer presented to the dermatology clinic
for evaluation of a pruritic eruption on the sun-
exposed areas of her body that began 2 months
after initiation of capecitabine treatment. The pa-
tient reported receiving ample sun exposure during
the summer months when she noted the onset of
the eruption. She also noted fingernail changes
over the same time frame. Her other medications
included prochlorperazine maleate 10 mg, hydro-
codone/acetaminophen 5 mg/325 mg, and denosu-
mab 120 mg subcutaneously every 4 weeks.
Examination revealed numerous violaceous, flat-
topped papules on extensor forearms, dorsal
hands, and anterior legs (Fig 1). Scaling and ery-
thema was observed in the periungual areas with
marked subungual hyperkeratosis. Diffuse ery-
thema was also noted of the palmar and plantar
surfaces. Examination of the oral cavity was unre-
markable. Fingernail clipping for histopathologic
and microbiologic evaluation of fungus was nega-
tive. Punch biopsy of the skin of her right
dorsal hand demonstrated a lichenoid interface
dermatitis with compact orthokeratosis of the
stratum corneum, multiple scattered melanophages,
and a few eosinophils in the dermis. The
clinical and histologic features were consistent
with a diagnosis of photosensitive lichenoid
drug eruption secondary to capecitabine treatment.
The patient was prescribed topical clobetasol pro-
pionate 0.05% ointment and systemic hydroxyzine,
and was recommended adherence to sun protec-
tion strategies. With these measures, she noted a
marked improvement in her eruption without any
changes in her chemotherapeutic regimen.
Capecitabine (Xeloda) is an oral prodrug of
fluorouracil (5-FU) used in the treatment of
advanced colorectal, esophageal, laryngeal, and
metastatic breast cancer.1 While 5-FU has been
used in the past for many solid tumors, it must be
administered intravenously. As an oral prodrug of
5-FU, capecitabine is easier to administer and moreconvenient for the patient; as such, its use has
increased in treating these patients.2 Some reports
have suggested a link between capecitabine use
and the development of a lichenoid photosensitive
eruption.3 Other cutaneous side effects have also
been reported, the most common of which is
palmar-plantar erythrodysesthesia, or hand-foot
syndrome, which occurs in as many as 50% of
those treated with capecitabine.4 This condition
causes tingling in the palms and soles that may
progress to burning pain 3 to 4 days later with
swelling, erythema, and possible skin ulceration.3
In addition, reports have linked the use of
capecitabine to other cutaneous presentations,
including oral lichenoid stomatitis,1 subacute
cutaneous lupus erythematosus,2 and other derma-
tologic conditions (Table I).
The reaction in our patient was unique because
of the simultaneous presentation of a photosensi-
tive lichenoid eruption, diffuse palmoplantar
erythema, and ungual toxicity, as evidenced by
the periungual erythema and subungual hyperker-
atosis. With the increasing use of capecitabine in
chemotherapeutic treatment for cancer, dermatol-
ogists should be aware of its potential cutaneous
side effects.
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